Physician profile
Brandy Mize
NPI 1790148203
$8,783.10
in general payments reported to CMS, 2019-2025
25 companies · $4,132 in 2025
The $4,132 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $252 · 2023: $3,262 · 2024: $1,137 · 2025: $4,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,232 · Education: $3,017 · Travel and Lodging: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.92 |
| Education | $3,017.38 |
| Travel and Lodging | $2,282.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,254.85 | 2024-2025 | |
| Medtronic, INC. | $2,135.08 | 2023 | Illumisite |
| Glaxosmithkline, LLC. | $837.76 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $462.31 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.11 | 2022-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $325.73 | 2022-2025 | Dupixent |
| Genzyme Corporation | $211.82 | 2023-2025 | |
| Insmed, INC. | $208.94 | 2022-2025 | Arikayce, Brinsupri |
| Amgen INC. | $192.43 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $155.26 | 2022-2025 | Glassia |
| United Therapeutics Corporation | $143.10 | 2023-2024 | Tyvaso |
| Grifols USA, LLC | $81.43 | 2023-2025 | Prolastin-C Liquid |
| Inogen, INC. | $68.70 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Inspire Medical Systems, INC. | $68.20 | 2023 | Inspire |
| Verona Pharma, INC. | $51.41 | 2025 | Ohtuvayre |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $49.45 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $43.31 | 2024-2025 | Purified Cortrophin Gel |
| Fisher & Paykel Healthcare INC | $33.24 | 2023 | Fisher & Paykel Healthcare |
| Mylan Specialty L.P. | $20.32 | 2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $19.41 | 2023 | Opsumit |
| Paratek Pharmaceuticals, INC. | $18.57 | 2023 | Nuzyra |
| Lilly USA, LLC | $18.33 | 2025 | Zepbound |
| Viatris Specialty LLC | $18.15 | 2025 | Yupelri |
| Boston Scientific Corporation | $15.62 | 2025 | Axonics |
| Resmed Corp | $15.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Mize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.